Loading
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06117566 by Shanghai Jiatan Pharmatech Co., Ltd, with 100 participants planned, started 2022-11-18 and due to reach its primary completion in 2025-11-09. Interventions recorded: WX390 and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Jiatan Pharmatech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/